Did You Miss These 3 High-Yielding Dividend Stocks In Health Care Sector From Wall Street's Most Accurate Analysts?
Portfolio Pulse from Avi Kapoor
The article discusses three high-yielding dividend stocks in the health care sector, with recent analyst ratings and news updates. Bristol-Myers Squibb (BMY) has a dividend yield of 4.81% but received a downgrade from B of A Securities and a Hold rating from Deutsche Bank. Organon & Co. (OGN) offers a 6.53% dividend yield, with Piper Sandler maintaining an Overweight rating and Morgan Stanley maintaining an Equal-Weight rating. CVS Health Corporation (CVS) has a 3.62% dividend yield, with Mizuho maintaining a Buy rating and Morgan Stanley maintaining an Overweight rating. BMY released data from a trial, OGN announced a new prescription product, and CVS is reportedly planning to close some pharmacies within Target stores.
January 30, 2024 | 12:49 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Bristol-Myers Squibb has a high dividend yield but was downgraded by B of A Securities and received a Hold rating from Deutsche Bank. The company also released positive trial data.
The downgrade by analysts may negatively impact the stock price, but the positive trial data could provide some counterbalance, leading to a neutral short-term impact.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80
NEUTRAL IMPACT
CVS Health Corporation has a moderate dividend yield and maintained Buy and Overweight ratings from analysts, despite slight price target reductions. The company may close some pharmacies within Target stores.
The maintained Buy and Overweight ratings suggest continued analyst confidence, while the pharmacy closures could be seen as a cost-saving measure, leading to a neutral short-term impact.
CONFIDENCE 75
IMPORTANCE 65
RELEVANCE 75
NEUTRAL IMPACT
Organon & Co. has a high dividend yield and maintained an Overweight rating from Piper Sandler, despite a lowered price target. The company announced the availability of a new prescription product.
While the price target was lowered, the Overweight rating and new product announcement could keep investor sentiment stable, resulting in a neutral short-term impact.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 70